Holen Sie sich die Stockscreener-App
2.04
29.57%
-0.835
Schlusskurs vom Vortag:
$2.875
Offen:
$2.02
24-Stunden-Volumen:
10.23M
Relative Volume:
2.60
Marktkapitalisierung:
$427.18M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-110.78M
KGV:
-1.9065
EPS:
-1.07
Netto-Cashflow:
$-75.59M
1W Leistung:
-38.82%
1M Leistung:
-40.96%
6M Leistung:
-62.98%
1J Leistung:
-34.04%
1-Tages-Spanne:
$1.99
$2.175
1-Wochen-Bereich:
$1.99
$3.36
52-Wochen-Spanne:
$1.99
$9.97
Humacyte Inc Stock (HUMA) Company Profile
Firmenname
Humacyte Inc
Sektor
Branche
Telefon
919-313-9633
Adresse
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Vergleichen Sie HUMA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
2.035 | 427.18M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
504.09 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.55 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
588.69 | 35.74B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.00 | 35.58B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.85 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2023-12-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-14 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-05-16 | Herabstufung | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | Eingeleitet | Cowen | Outperform |
| 2021-09-24 | Eingeleitet | Oppenheimer | Outperform |
| 2021-09-22 | Eingeleitet | BTIG Research | Buy |
| 2021-09-16 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Humacyte Inc Aktie (HUMA) Neueste Nachrichten
Biggest stock movers Wednesday: GME, HUMA, and more (NASDAQ:HUMA) - Seeking Alpha
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025 - TradingView
Major Biotech Innovation Updates Expected in Humacyte Q4 Earnings Call - StockTitan
Humacyte stock plunges on public offering pricing By Investing.com - Investing.com Australia
Dollar Tree, GameStop, Humacyte - TradingView
US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert - Benzinga
Humacyte stock slides on pricing public offering of units to raise $50M - MSN
Humacyte Secures $50M Funding: Major Push for SYMVESS Commercialization - StockTitan
Humacyte sets $2 stock offering, aims for $50 million - Investing.com
Humacyte Prices Public Offering Of 25 Million Shares At $2.00 Per Share - Marketscreener.com
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock - Yahoo Finance
Humacyte announces public stock offering for expansion By Investing.com - Investing.com South Africa
Humacyte Shares Plunge After Hours: Here's Why - Benzinga
Humacyte announces public stock offering for expansion - Investing.com India
Humacyte down 13% amid reports that FDA approved device despite warnings - Seeking Alpha
Humacyte Announces Proposed Public Offering Of Common Stock - Marketscreener.com
Humacyte Secures Major Funding Round: TD Cowen, Barclays Back SYMVESS Commercialization - StockTitan
Humacyte To Present Fourth Quarter And Full Year Financial Results And Provide Corporate Update On March 28, 2025 - Marketscreener.com
Humacyte, Inc. (HUMA) Flat As Market Gains: What You Should Know - MSN
Humacyte: Symvess' Approval And Launch Are Just The First Steps To Adoption (Downgrade) - Seeking Alpha
Class Action Filed Against Humacyte, Inc. (HUMA) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025HUMA - ACCESS Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Humacyte, Inc. of Class Action Lawsuit and Upcoming DeadlinesHUMA - ACCESS Newswire
Individual investors who hold 41% of Humacyte, Inc. (NASDAQ:HUMA) gained 11%, institutions profited as well - Simply Wall St
HUMACYTE Earnings Preview: Recent $HUMA Insider Trading, Hedge Fund Activity, and More - Nasdaq
Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday? - AOL
Humacyte, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - ACCESS Newswire
Why Humacyte Stock Is Trading 15% Higher Monday - MSN
HC Wainwright Reiterates Buy Rating for Humacyte (NASDAQ:HUMA) - Defense World
HUMA stock touches 52-week low at $2.81 amid market shifts - Investing.com Australia
HUMA stock touches 52-week low at $2.81 amid market shifts By Investing.com - Investing.com South Africa
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Humacyte’s Symvess: A Transformative Solution in Vascular Trauma Care with Strong Market Potential - TipRanks
Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics - The Manila Times
Humacyte Announces Economic Value of Symvess in Budget Impact Model Publication - Nasdaq
New Study: Humacyte's Symvess Cuts Trauma Center Costs by $33,000 Per Patient - StockTitan
Humacyte’s SYMVESS Launch and Strategic Positioning Drive Buy Rating - TipRanks
Humacyte (NASDAQ:HUMA) Earns Buy Rating from D. Boral Capital - Defense World
Rhumbline Advisers Acquires 5,005 Shares of Humacyte, Inc. (NASDAQ:HUMA) - Defense World
Benchmark maintains Humacyte stock Buy rating, $17 target - Investing.com India
Benchmark maintains Humacyte stock Buy rating, $17 target By Investing.com - Investing.com South Africa
Humacyte, Inc. (NASDAQ:HUMA) Receives $13.71 Average Target Price from Analysts - Defense World
Trestle Bio Announces Research Collaboration with Humacyte - BioSpace
Humacyte Partners With Trestle Biotherapeutics on Bioengineered Kidney Research -March 06, 2025 at 09:16 am EST - Marketscreener.com
Humacyte, Trestle Biotherapeutics announce research collaboration - TipRanks
Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade - MSN
Shareholders that Lost Money on Humacyte, Inc. (HUMA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025 - The Manila Times
Will Humacyte's First-in-Class Bioengineered Vessel Transform Trauma Care? Investors to Get Answers - StockTitan
Atria Wealth Solutions Inc. Makes New Investment in Humacyte, Inc. (NASDAQ:HUMA) - Defense World
Buy Rating for Humacyte Driven by Symvess Launch and Economic Advantages - TipRanks
Finanzdaten der Humacyte Inc-Aktie (HUMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.66%
4.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):